Dosage of cidofovir and toxicity
| . | Patients receiving CDV 3 mg/kg n = 24 . | Patients receiving CDV 4.5 to 5 mg/kg n = 56 . | P value . |
|---|---|---|---|
| Median (range) of therapy duration (weeks) | 2.5 (1-9) | 3 (1-26) | NS |
| No. (proportion) of patients receiving concomitant nephtotoxic drugs | |||
| Cyclosporine | 22 (91.6%) | 43 (76.7%) | .09 |
| Tacrolimus | 1 (4.1%) | 2 (3.6%) | NS |
| Other nephrotoxic drugs | 8 (33.3%) | 31 (55.4%) | .08 |
| Median baseline s-creatinine (mg/dL) | 1.07 | 0.8 | .04 |
| No. (proportion) of patients who developed nephrotoxicity defined as: | |||
| >1.5 ≤ 2.0 × baseline s-creatinine | 2/24 | 4/56 | NS |
| ≥2.0 × baseline s-creatinine | 2/24 | 3/56 | NS |
| Renal failure | 0/24 | 1/56 | NS |
| Proteinuria | 1/24 | 10/56 | NS |
| Nausea/vomiting | 0/24 | 6/56 | .09 |
| Rash | 2/24 | 0/56 | NS |
| Ophthalmological toxicity | 2/24 | 0/56 | NS |
| Thrombocytopenia | 0/24 | 2/56 | NS |
| . | Patients receiving CDV 3 mg/kg n = 24 . | Patients receiving CDV 4.5 to 5 mg/kg n = 56 . | P value . |
|---|---|---|---|
| Median (range) of therapy duration (weeks) | 2.5 (1-9) | 3 (1-26) | NS |
| No. (proportion) of patients receiving concomitant nephtotoxic drugs | |||
| Cyclosporine | 22 (91.6%) | 43 (76.7%) | .09 |
| Tacrolimus | 1 (4.1%) | 2 (3.6%) | NS |
| Other nephrotoxic drugs | 8 (33.3%) | 31 (55.4%) | .08 |
| Median baseline s-creatinine (mg/dL) | 1.07 | 0.8 | .04 |
| No. (proportion) of patients who developed nephrotoxicity defined as: | |||
| >1.5 ≤ 2.0 × baseline s-creatinine | 2/24 | 4/56 | NS |
| ≥2.0 × baseline s-creatinine | 2/24 | 3/56 | NS |
| Renal failure | 0/24 | 1/56 | NS |
| Proteinuria | 1/24 | 10/56 | NS |
| Nausea/vomiting | 0/24 | 6/56 | .09 |
| Rash | 2/24 | 0/56 | NS |
| Ophthalmological toxicity | 2/24 | 0/56 | NS |
| Thrombocytopenia | 0/24 | 2/56 | NS |
CDV indicates cidofovir; s-creatinine, serum creatinine.